Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses

被引:64
作者
Balasuriya, UBR
Heidner, HW
Davis, NL
Wagner, HM
Hullinger, PJ
Hedges, JF
Williams, JC
Johnston, RE
Wilson, WD
Liu, IK
MacLachlan, NJ
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Bernard & Gloria Salick Equine Viral Dis Lab, Davis, CA 95616 USA
[2] Univ Texas, Div Life Sci, San Antonio, TX 78249 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Calif Dept Food & Agr, Sacramento, CA 95814 USA
[5] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA
[6] Univ Calif Davis, Sch Vet Med, Dept Populat Hlth & Reprod, Davis, CA 95616 USA
关键词
vaccination; EAV; VEE;
D O I
10.1016/S0264-410X(01)00485-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Replicon particles derived from a vaccine strain of Venezuelan equine encephalitis (VEE) virus were used as vectors for expression in vivo of the major envelope proteins (G(L) and M) of equine arteritis virus (EAV), both individually and in heterodimer form (G(L)/M). The immunogenicity of the different replicons was evaluated in horses, as was their ability to protectively immunize horses against intranasal and intrauterine challenge with a virulent strain of EAV (EAV KY84). Horses immunized with replicons that express both the G(L) and M proteins in heterodimer form developed neutralizing antibodies to EAV, shed Little or no virus, and developed only mild or inapparent signs of equine viral arteritis (EVA) after challenge with EAV KY84. In contrast, unvaccinated horses and those immunized with replicons expressing individual EAV envelope proteins (M or G(L)) shed virus for 6-10 days in their nasal secretions and developed severe signs of EVA after challenge. These data confirm that replicons that co-express the G(L) and M envelope proteins effectively, induce EAV neutralizing antibodies and protective immunity in horses. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1609 / 1617
页数:9
相关论文
共 49 条
[1]   IDENTIFICATION OF A NEUTRALIZATION SITE IN THE MAJOR ENVELOPE GLYCOPROTEIN (G(L)) OF EQUINE ARTERITIS VIRUS [J].
BALASURIYA, UBR ;
MACLACHLAN, NJ ;
DEVRIES, AAF ;
ROSSITTO, PV ;
ROTTIER, PJM .
VIROLOGY, 1995, 207 (02) :518-527
[2]   A 29K ENVELOPE GLYCOPROTEIN OF EQUINE ARTERITIS VIRUS EXPRESSES NEUTRALIZATION DETERMINANTS RECOGNIZED BY MURINE MONOCLONAL-ANTIBODIES [J].
BALASURIYA, UBR ;
ROSSITTO, PV ;
DEMAULA, CD ;
MACLACHLAN, NJ .
JOURNAL OF GENERAL VIROLOGY, 1993, 74 :2525-2529
[3]   Neutralization determinants of laboratory strains and field isolates of equine arteritis virus: Identification of four neutralization sites in the amino-terminal ectodomain of the G(L) envelope glycoprotein [J].
Balasuriya, UBR ;
Patton, JF ;
Rossitto, PV ;
Timoney, PJ ;
McCollum, WH ;
MacLachlan, NJ .
VIROLOGY, 1997, 232 (01) :114-128
[4]   Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis [J].
Balasuriya, UBR ;
Hedges, JF ;
Nadler, SA ;
McCollum, WH ;
Timoney, PJ ;
MacLachlan, NJ .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :1949-1958
[5]  
Balasuriya UBR, 1998, J AM VET MED ASSOC, V213, P1586
[6]   Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant venezuelan equine encephalitis virus replicon particles [J].
Balasuriya, UBR ;
Heidner, HW ;
Hedges, JF ;
Williams, JC ;
Davis, NL ;
Johnston, RE ;
MacLachlan, NJ .
JOURNAL OF VIROLOGY, 2000, 74 (22) :10623-10630
[7]   Equine arteritis virus derived from an infectious cDNA clone is attenuated and genetically stable in infected stallions [J].
Balasuriya, UBR ;
Snijder, EJ ;
van Dinten, LC ;
Heidner, HW ;
Wilson, WD ;
Hedges, JF ;
Hullinger, PJ ;
MacLachan, NJ .
VIROLOGY, 1999, 260 (01) :201-208
[8]   Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy [J].
Caley, IJ ;
Betts, MR ;
Davis, NL ;
Swanstrom, R ;
Frelinger, JA ;
Johnston, RE .
VACCINE, 1999, 17 (23-24) :3124-3135
[9]   Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector [J].
Caley, IJ ;
Betts, MR ;
Irlbeck, DM ;
Davis, NL ;
Swanstrom, R ;
Frelinger, JA ;
Johnston, RE .
JOURNAL OF VIROLOGY, 1997, 71 (04) :3031-3038
[10]  
Cavanagh D, 1997, ARCH VIROL, V142, P629